ENTR-701

Entrada Therapeutics has received MHRA authorization to commence ELEVATE-44-201, a Phase I/II trial evaluating ENTR-601-44 for Duchenne muscular dystrophy patients with exon 44 skipping mutations.

The FDA has approved JOURNAVX™ (suzetrigine) as a first-in-class, non-opioid treatment for moderate-to-severe acute pain in adults.

The myotonic dystrophy therapeutic landscape is experiencing a surge in R&D, with over 20 companies actively involved in developing 22+ novel therapies.

Vertex Pharmaceuticals increased its full-year product revenue guidance to $10.8 billion to $10.9 billion, driven by strong performance in CF and the early launch of CASGEVY.